{
  "nctId": "NCT03290898",
  "briefTitle": "REPLACE: Can Exercise Replace Inhaled Corticosteroid Treatment in Asthma? A RCT",
  "officialTitle": "REPLACE: Can Exercise Replace Inhaled Corticosteroid Treatment in Asthma? A Randomized Clinical Trial",
  "protocolDocument": {
    "nctId": "NCT03290898",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2017-10-02",
    "uploadDate": "2020-12-23T08:58",
    "size": 1194438,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03290898/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "DOUBLE",
  "enrollmentInfo": {
    "enrollmentCount": 150,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2017-10-13",
    "completionDate": "2020-12-04",
    "primaryCompletionDate": "2020-06-26",
    "firstSubmitDate": "2017-09-18",
    "firstPostDate": "2017-09-25"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Asthma (The diagnose of asthma is based on symptoms and at least one positive asthma test the last 5 years (AHR to either mannitol or methacholine, reversibility to beta2-agonist, peak flow variation or positive eucapnic voluntary hyperventilation test))\n* ACQ ≥ 1 and ≤ 2.5\n* On a daily dose of ICS at a minimum of 400 µg budesonide or equivalent ICS for 3 months and with no changes in asthma medicine 4 weeks prior to enrollment\n* Untrained (no participation in vigorous exercise for more than 1 hour per week during the last 2 month)\n* Capable of exercising on bike\n\nExclusion Criteria:\n\n* Unable to speak and understand Danish\n* Infection within 4 weeks prior to visit 100\\*\n* Asthma exacerbation within 4 weeks prior to visit 100\\*\n* Hospitalized for an asthma attack during the last 2 months\n* Treatment with immunotherapy within 5 T½ of the treatment drug prior to visit 100\n* Initiation of allergen immunotherapy within 3 months prior to visit 100 or plan to begin therapy during study period\n* Treatment with peroral prednisolone\n* Respiratory: other chronic pulmonary disease of clinically significance\n* Cardiovascular: Unstable ischemic heart disease, myocardial infarction within the last 12 months, symptomatic heart failure (NYHA III-IV or EF \\<40%), symptomatic heart arrhythmia (documented with ECG), uncontrolled hypertension (\\>155/100)\n* Pregnancy or breastfeeding or planned pregnancy within the next 12 months\n* Other inflammatory or metabolic diseases with the exception of rhinitis, atopy and well-controlled hypothyroidism treated with or without Eltroxin\n* Vaccination less than 2 weeks prior to any visit\n* Current or former smokers with \\> 20 pack years\n* Subjects, who by investigators determination, will not be able to adhere to study protocol\n\n  * If patients are excluded due to a recent infection or exacerbation they can undergo re-screening after a total of 4 weeks after end of exacerbation treatment/clearing the infection.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "75 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Reduced inhaled corticosteroid (ICS) 6 months",
        "description": "The proportion of participants at 6 months that have been down-titrated in ICS dose by at least 25% compared to the participants' baseline dose",
        "timeFrame": "6 months +/- 7 days"
      }
    ],
    "secondary": [
      {
        "measure": "Reduced inhaled corticosteroid (ICS) 12 months",
        "description": "The proportion of participants at 12 months that have been down-titrated in ICS dose by at least 25 % compared to baseline.",
        "timeFrame": "12 months +/- 7 days"
      },
      {
        "measure": "Cumulated ICS 6 months",
        "description": "Change from baseline in cumulated dose of ICS at 6 months",
        "timeFrame": "6 months +/- 7 days"
      },
      {
        "measure": "Cumulated ICS 12 months",
        "description": "Change from baseline in cumulated dose of ICS at 12 months",
        "timeFrame": "12 months +/- 7 days"
      },
      {
        "measure": "Cumulated Long acting beta2 agonists (LABA) 6 months",
        "description": "Change from baseline in cumulated dose of LABA at 6 months",
        "timeFrame": "6 months +/- 7 days"
      },
      {
        "measure": "Cumulated LABA 12 months",
        "description": "Change from baseline in cumulated dose of LABA at 12 months",
        "timeFrame": "12 months +/- 7 days"
      },
      {
        "measure": "Exacerbation rate 6 months",
        "description": "Number of exacerbations (moderate-severe) at 6 months",
        "timeFrame": "6 months +/- 7 days"
      },
      {
        "measure": "Exacerbation rate 12 months",
        "description": "Number of exacerbations (moderate-severe) at 12 months",
        "timeFrame": "12 months +/- 7 days"
      },
      {
        "measure": "miniAQLQ 6 months",
        "description": "Change from baseline in Asthma life quality evaluated by miniAQLQ at 6 months",
        "timeFrame": "6 months +/- 7 days"
      },
      {
        "measure": "miniAQLQ 12 months",
        "description": "Change from baseline in Asthma life quality evaluated by miniAQLQ at 12 months",
        "timeFrame": "12 months +/- 7 days"
      },
      {
        "measure": "Fraction of exhaled Nitrogen Oxid 6 months",
        "description": "Change from baseline in Airway inflammation evaluated by FeNO at 6 months",
        "timeFrame": "6 months +/- 7 days"
      },
      {
        "measure": "Fraction of exhaled Nitrogen Oxid 12 months",
        "description": "Change from baseline in Airway inflammation evaluated by FeNO at 12 months",
        "timeFrame": "12 months +/- 7 days"
      },
      {
        "measure": "Sputum cell count 6 months",
        "description": "Change from baseline in Airway inflammation evaluated by sputum cell count at 6 months",
        "timeFrame": "6 months +/- 7 days"
      },
      {
        "measure": "Sputum cell count 12 months",
        "description": "Change from baseline in Airway inflammation evaluated by sputum cell count at 12 months",
        "timeFrame": "12 months +/- 7 days"
      },
      {
        "measure": "Systemic inflammation 6 months",
        "description": "Change from baseline in systemic inflammation evaluated by blood eosinophilic, hsCRP and inflammatory cytokines (e.g. IL-6 and IL-8) and TNF-alfa at 6 months",
        "timeFrame": "6 months +/- 7 days"
      },
      {
        "measure": "Systemic inflammation 12 months",
        "description": "Change from baseline in systemic inflammation evaluated by blood eosinophilic, hsCRP and inflammatory cytokines (e.g. IL-6 and IL-8) and TNF-alfa at 12 months",
        "timeFrame": "12 months +/- 7 days"
      },
      {
        "measure": "Airway hyperresponsiveness",
        "description": "Change from baseline in airway hyperresponsiveness measured by methacholine test at 6 months",
        "timeFrame": "6 months +/- 7 days"
      },
      {
        "measure": "FEV1 6 months",
        "description": "Change from baseline in lung function evaluated by FEV1 at 6 months",
        "timeFrame": "6 months +/- 7 days"
      },
      {
        "measure": "FVC 6 months",
        "description": "Change from baseline in lung function evaluated by FVC at 6 months",
        "timeFrame": "6 months +/- 7 days"
      },
      {
        "measure": "FEV1 12 months",
        "description": "Change from baseline in lung function evaluated by FEV1 at 12 months",
        "timeFrame": "12 months +/- 7 days"
      },
      {
        "measure": "FVC 12 months",
        "description": "Change from baseline in lung function evaluated by FVC at 12 months",
        "timeFrame": "12 months +/- 7 days"
      },
      {
        "measure": "Cardiopulmonary fitness",
        "description": "Change from baseline in cardiopulmonary fitness evaluated by maximum oxygen consumption at 6 months (VO2max)",
        "timeFrame": "6 months +/- 7 days"
      },
      {
        "measure": "Change in fat and muscle composition (DEXA scan)",
        "description": "Change from baseline in fat and muscle composition evaluated by DEXA scan",
        "timeFrame": "6 months +/- 7 days"
      }
    ],
    "other": [
      {
        "measure": "Eosinophilic subpopulation - exploratory analyses 6 months",
        "description": "To evaluate the effect of the intervention in sub-populations of asthmatics using different cut-off values of blood eosinophilics. Both regarding primary outcome and secondary outcomes.",
        "timeFrame": "6 months +/- 7 days"
      },
      {
        "measure": "Eosinophilic subpopulation - exploratory analyses 12 months",
        "description": "To evaluate the effect of the intervention in sub-populations of asthmatics using different cut-off values of blood eosinophilics with regards to secondary outcomes at 12 months.",
        "timeFrame": "12 months +/- 7 days"
      }
    ]
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 22,
      "otherCount": 2,
      "totalCount": 25
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:29:22.361Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}